“Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Clostridium Difficile Infections Market.
The Clostridium Difficile Infections Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the emerging therapies for the treatment of Clostridium Difficile Infections and the aggregate therapies developed by major pharma companies.
-
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
-
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Clostridium Difficile Infections market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Route of Administration
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intra-articular
-
Intraocular
-
Intrathecal
-
Intravenous
-
Ophthalmic
-
Oral
-
Parenteral
-
Subcutaneous
-
Topical
-
Transdermal
Molecule Type
Products have been categorized under various Molecule types such as
-
Oligonucleotide
-
Peptide
-
Small molecule
Learn How the Ongoing Clinical & Commercial Activities will Affect the Clostridium Difficile Infections Therapeutic Segment @
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Landscape
There are approx. 25+ key companies developing therapies for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). Currently, Rebiotix is leading the therapeutics market with its Clostridium Difficile Infections (Clostridium Difficile Associated Disease) drug candidates in the most advanced stage of clinical development.
Some of the Key Companies in the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Market Include:
Acurx Pharmaceuticals, Adiso Therapeutics, Biovertis AG, Crestone, Da Volterra, Deinove, Destiny Pharma, Ferring Pharmaceuticals, Finch Therapeutics Group, GlaxoSmithKline, Lumen Bioscience, MGB Biopharma, MicroPharm Ltd., Mikrobiomik Healthcare Company S.L., Oragenics, Pfizer, Rebiotix, Recursion Pharmaceuticals, SAb Biotherapeutics, Seres Therapeutics/Nestlé Health Science, Summit Therapeutics, Valneva, Vedanta Biosciences, Inc., and others.
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapies Covered in the Report Include:
-
ADS 024: Adiso Therapeutics
-
CP101: Finch Therapeutics
-
Ibezapolstat: Acurx Pharmaceuticals
-
MGB-BP-3: MGB Biopharma
-
NTCD-M3: Destiny Pharma
-
PF-06425090 (C. difficile vaccine): Pfizer
-
RBX 2660: Rebiotix
-
REBYOTA (RBX2660): Ferring Pharmaceuticals
-
Ridinilazole: Summit Therapeutics
-
SER 109: Seres Therapeutics
-
VE303: Vedanta Biosciences
And Many Others
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Clostridium Difficile Infections Current Treatment Patterns
4. Clostridium Difficile Infections – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Clostridium Difficile Infections Late Stage Products (Phase-III)
7. Clostridium Difficile Infections Mid-Stage Products (Phase-II)
8. Clostridium Difficile Infections Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Clostridium Difficile Infections Discontinued Products
13. Clostridium Difficile Infections Product Profiles
14. Key Companies in the Clostridium Difficile Infections Market
15. Key Products in the Clostridium Difficile Infections Therapeutics Segment
16. Dormant and Discontinued Products
17. Clostridium Difficile Infections Unmet Needs
18. Clostridium Difficile Infections Future Perspectives
19. Clostridium Difficile Infections Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Peripheral Neuritis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Peripheral Neuritis market trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan). Moreover, it covers the current treatment practices, emerging drugs, market share of individual therapies, treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Peripheral Neuritis market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/